Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.

@article{Gong2005ComparisonOH,
  title={Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.},
  author={Yun Guo Gong and Daniel J. Booser and Nour Sneige},
  journal={Cancer},
  year={2005},
  volume={103 9},
  pages={1763-9}
}
BACKGROUND Accurate assessment of HER-2 status is necessary prior to anti-HER-2 antibody (trastuzumab) therapy for metastatic breast carcinoma. However, controversy exists regarding whether to assess HER-2 status in the primary tumor or in metastatic lesions. It is also unclear whether HER-2 status can change during disease progression or after chemotherapy. METHODS Breast carcinoma samples from 60 women with known HER-2 status in both primary tumors and paired metastases (locoregional… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 87 extracted citations

Similar Papers

Loading similar papers…